We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

162 hedge funds and large institutions have $1.22B invested in Acorda Therapeutics in 2018 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 53 increasing their positions, 43 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

93% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 15

23% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 43

11% more capital invested

Capital invested by funds: $1.09B → $1.22B (+$123M)

8% more funds holding

Funds holding: 150 → 162 (+12)

57% less call options, than puts

Call options by funds: $17.2M | Put options by funds: $39.5M

Holders
162
Holders Change
+12
Holders Change %
+8%
% of All Funds
3.71%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
29
Increased
53
Reduced
43
Closed
15
Calls
$17.2M
Puts
$39.5M
Net Calls
-$22.4M
Net Calls Change
-$14.1M

Top Buyers

Rank Fund Capital Flow
1
HM
HealthCor Management
New York
+$19.2M
2
Millennium Management
Millennium Management
New York
+$13.4M
3
FAM
Fred Alger Management
New York
+$9.29M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.37M
5
Renaissance Technologies
Renaissance Technologies
New York
+$5.18M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$26.6M
2
AQR Capital Management
AQR Capital Management
Connecticut
-$7.79M
3
Morgan Stanley
Morgan Stanley
New York
-$7.78M
4
BIM
Bogle Investment Management
Massachusetts
-$5.35M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$5.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
MCIM
126
Meadow Creek Investment Management
Georgia
$207K – – –
XK
127
Xact Kapitalforvaltning
Sweden
$206K +$219K +73 New
EP
128
Elkfork Partners
Oregon
$162K – – –
CG
129
Cutler Group
California
$147K +$105K +35 +206%
RCM
130
Riverhead Capital Management
Delaware
$132K – – –
TAM
131
Tyers Asset Management
Texas
$118K – – –
AIP
132
Ameritas Investment Partners
Nebraska
$88K – – –
Zurich Cantonal Bank
133
Zurich Cantonal Bank
Switzerland
$86K – – –
Walleye Trading
134
Walleye Trading
New York
$61K +$65.9K +22 New
LTFS
135
Ladenburg Thalmann Financial Services
Florida
$52K – – –
PCM
136
Prelude Capital Management
New York
$43K -$38.9K -13 -46%
Macquarie Group
137
Macquarie Group
Australia
$43K +$35.9K +12 +400%
NIT
138
NumerixS Investment Technologies
British Columbia, Canada
$40K +$41.9K +14 New
PNC Financial Services Group
139
PNC Financial Services Group
Pennsylvania
$38K +$15K +5 +63%
LIA
140
LS Investment Advisors
Michigan
$36K +$2.99K +1 +8%
VCM
141
Versant Capital Management
Arizona
$32K – – –
Citigroup
142
Citigroup
New York
$32K +$12K +4 +57%
MAM
143
Meeder Asset Management
Ohio
$29K -$15K -5 -33%
FWM
144
Focused Wealth Management
New York
$24K – – –
TRCT
145
Tower Research Capital (TRC)
New York
$21K -$15K -5 -42%
Bank of Montreal
146
Bank of Montreal
Ontario, Canada
$18K – – –
SEI Investments
147
SEI Investments
Pennsylvania
$16K +$18K +6 New
SWA
148
Sutton Wealth Advisors
Florida
$12.8K – – –
AIM
149
Advantage Investment Management
Iowa
$12K +$12K +4 New
RA
150
Royce & Associates
New York
$10K +$8.98K +3 New
4 5
6
7 8

ACOR Hedge Fund Activity: Q1 2018 in Review

162 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2018, worth a combined $1.22B — up 11% from $1.09B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ACOR positions and 15 closed out — a net gain of 14 holders — while 53 added to existing stakes and 43 trimmed.

The largest buyer was HealthCor Management, opening a new position worth an estimated $19.2M. The largest seller was Invesco, cutting an estimated $26.6M.

  • 162 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2018, up from 150 in Q4 2017.
  • Funds reported $1.22B of Acorda Therapeutics stock for Q1 2018, up 11% quarter-over-quarter.
  • 29 funds opened new Acorda Therapeutics positions in Q1 2018 and 15 closed out, a net change of +14 holders.
  • The largest Acorda Therapeutics buyer in Q1 2018 was HealthCor Management, an estimated $19.2M added.
  • The largest Acorda Therapeutics seller in Q1 2018 was Invesco, an estimated $26.6M sold.

Based on aggregated 13F filings for Q1 2018.